SCHEMBL20599686

SCHEMBL20599686

O=C(O)C1(S(=O)(=O)N2CCC2)CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.37
TSHR P16473 2/20 0.37
NPSR1 Q6W5P4 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
CYP2C19 P33261 1/20 0.32
CYP2D6 P10635 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.30
HPGD P15428 1/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20599615 0.96 CA1 (0.38) KMT2ATSHRNPSR1CA1CA2
SCHEMBL23326947 0.72 NPSR1 (0.40) TSHRNPSR1ALDH1A1CYP2C19LMNA
SCHEMBL21598377 0.70 NPSR1 (0.43) TSHRNPSR1ALDH1A1CYP2C19LMNA
SCHEMBL9414299 0.70 NPSR1 (0.39) TSHRNPSR1ALDH1A1CYP2C19LMNA
SCHEMBL27651237 0.70 NPSR1 (0.39) TSHRNPSR1ALDH1A1CYP2C19LMNA
SCHEMBL21797972 0.69 NPSR1 (0.53) KMT2ATSHRNPSR1ALDH1A1MEN1
SCHEMBL9414297 0.68 NPSR1 (0.38) NPSR1CYP2C19LMNASMN1; SMN2
SCHEMBL25355553 0.68 CA1 (0.42) KMT2ATSHRCA1CA2ALDH1A1
SCHEMBL20599537 0.63 NPSR1 (0.41) NPSR1ALDH1A1CYP2C19SMN1; SMN2
SCHEMBL31030372 0.63 GAA (0.39) KMT2ATSHRCA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3645516-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS Janssen Pharmaceutica NV (BE) 2020-05-06 EP disclosed
WO-2019001420-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2019-01-03 WO disclosed